New diabetes drug under Real-World watch
NCT ID NCT07433192
First seen Feb 26, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study is observing how well the diabetes drug luseogliflozin (Lusefi®) controls blood sugar and is tolerated by adults with type 2 diabetes in everyday medical practice. About 300 people will take part, and researchers will track changes in blood sugar levels, weight, and blood pressure over time. The goal is to see how the drug performs outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GBUZ hospital
RECRUITINGAnapa, Russia
Conditions
Explore the condition pages connected to this study.